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Clonal haematopoiesis is not prevalent in survivors of
childhood cancer
Clonal haematopoiesis driven by leukaemia-associated
somatic mutations is a common feature of ageing (Link &
Walter, 2016). This phenomenon, termed clonal haemato-
poiesis of indeterminate potential (CHIP), is associated
with an increased risk of haematological malignancies and
all-cause mortality (Link & Walter, 2016). Recent empirical
evidence and computational models suggest that mutation
acquisition may not be the major rate-limiting factor in the
emergence of CHIP (Altrock et al, 2015; McKerrell et al,
2015; Link & Walter, 2016; Young et al, 2016). Instead, clo-
nal expansion of mutant haematopoietic stem cells (HSCs)
probably reflects the interaction between the effects of dri-
ver mutations and selection pressures prevailing in the bone
marrow microenvironment (Link & Walter, 2016). Notably,
cytotoxic therapies have been shown to favour expansion of
pre-malignant haematopoietic clones (Link & Walter, 2016).
Furthermore, both adult and paediatric cancer patients trea-
ted with intensive chemoradiotherapy display an earlier
onset of ageing-associated morbidities and an elevated risk
of therapy-related myeloid neoplasms (t-MN) and other
secondary malignancies (Rowland & Bellizzi, 2014). A
recent study in adult cancer patients found that CHIP was
more prevalent than in the general population and was
strongly associated with t-MN and overall mortality (Gibson
et al, 2017). Although CHIP is extremely rare in healthy
young individuals, its prevalence and prognostic significance
in paediatric cancer patients has not been studied. We
therefore performed targeted deep sequencing of peripheral
blood DNA from 84 childhood cancer survivors to search
for subclonal mutations common in t-MN and adult clonal
haematopoiesis. No individuals with somatic variants at
these loci were identified. Whilst our findings could be
explained by a rarity of driver mutations, the fact that
human HSCs accrue somatic variants from the first decade
of life (Welch et al, 2012) proposes the alternative possibil-
ity that such mutations may not confer clonal advantage in
the young.
We obtained peripheral blood DNA samples from patients
enrolled on long-term follow-up after treatment for a paedi-
atric malignancy and from three age-matched controls with
no cancer history. Written informed consent was obtained
for sample collection and DNA sequencing from all patients
or their guardian in accordance with the Declaration of Hel-
sinki and protocols approved by the relevant institutional
ethics committees (approval numbers 09REG2015, 1-09/12/
2015). The median age at cancer diagnosis was 45 years, and
the commonest malignancies were acute lymphoblastic leu-
kaemia (n = 21), neuroblastoma (n = 17) and non-Hodgkin
lymphoma (n = 10). Nineteen patients had received a HSC
transplant (8 allogeneic and 11 autologous). The median
interval between completion of cancer treatment and blood
sampling was 6 years (range 2–25). Patient characteristics are
summarized in Table SI.
We performed targeted next generation sequencing (NGS)
using multiplex polymerase chain reaction to amplify 32
regions of 14 genes frequently mutated in CHIP or t-MN
(Table I) (McKerrell et al, 2015; Link & Walter, 2016; Gib-
son et al, 2017). For this we extended a previously validated
assay that detected clonal haemopoiesis in 26% of unselected
adults (McKerrell et al, 2015), to include all coding exons of
TP53 and PPM1D, genes implicated in t-MN pathogenesis
(Rowland & Bellizzi, 2014; Link & Walter, 2016; Gibson
et al, 2017). Primer design and sequencing was performed as
described previously (McKerrell et al, 2015); see Table SII for
primer sequences. Reads were aligned to human genome
build GRCh37 using the Burrows-Wheeler Aligner (Li &
Durbin, 2010) and analysed for somatic single nucleotide
variants. Allele counts were generated using an in-house
script (https://github.com/cancerit/alleleCount), considering
only loci with ≥1000 reads and minimum base and mapping
quality of 25 and 35, respectively. Somatic mutations with
Table I. Genomic regions sequenced.
Gene Chromosome Target codon/exon
NRAS 1 p.G12
SF3B1 2 p.K666; p.K700
DNMT3A 2 p.R882
IDH1 2 p.R132
KIT 4 exon 17
NPM1 5 exon 12
JAK2 9 p.V617
KRAS 12 p.G12
IDH2 15 p.R140; p.R172
PPM1D 17 exons 1–6
TP53 17 exons 1–12
SRSF2 17 p.P95
ASXL1 20 exon 12
U2AF1 21 p.S34; p.Q157
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variant allele frequency (VAF) ≥0008 (McKerrell et al, 2015)
were sought and examined visually and by interrogation with
the Shearwater algorithm (https://github.com/mg14/dee
pSNV) (Gerstung et al, 2014).
The median sequencing depth across regions of interest
was 53 9 103. No somatic mutations with VAF ≥ 0008
were observed in any of our patients or controls, demon-
strating that CHIP driven by mutations at these loci is not
prevalent in young individuals who have received cytotoxic
treatment. By contrast, Gibson et al (2017) identified post-
chemotherapy CHIP (VAF > 002) in 299% of 401 adult
lymphoma patients. Notably, mutations in PPM1D, a regula-
tor of TP53, were the commonest CHIP drivers (Gibson
et al, 2017). Similarly, several smaller studies have demon-
strated clonal expansion in older patients undergoing
chemoradiotherapy for other cancers (Link & Walter, 2016).
An investigation of haematopoietic clonal dynamics in 15
adult acute myeloid leukaemia patients found that, after
induction chemotherapy, five had marked expansion of
clones unrelated to their leukaemia (Link & Walter, 2016).
Most clones carried canonical leukaemia mutations and con-
tinued to expand years after remission (Link & Walter,
2016). In a study exploring the clonal origins of t-MN,
TP53-mutated clones expanded dramatically after cytotoxic
treatment, whereas the same mutations demonstrated very
modest clonal advantage in healthy individuals (Link & Wal-
ter, 2016). In light of the above, our findings have two plau-
sible explanations: (i) that somatic driver mutations are very
uncommon in young individuals even after exposure to
chemotherapy or (ii) that accrual of such mutations is insuf-
ficient to trigger clonal expansion in this age group. The lat-
ter is supported by findings that oncogenic mutations begin
accumulating early in life (Welch et al, 2012) and that can-
cer-associated mutations are less able to drive clonal expan-
sion in young compared to old stem cells (Zhu et al, 2016).
The fact that bona-fide driver mutations do not always lead
to haematopoietic clonal expansion, even after several years,
was highlighted by Young et al (2016), using ultra-sensitive
sequencing. Therefore our results should not be taken to
reflect absence of potentially oncogenic HSC mutations in
young cancer survivors. Rather, it is possible that even
canonical leukaemogenic mutations may not commonly drive
clonal outgrowth in children and young adults despite expo-
sure to extreme haematopoietic stress, implicating age-related
changes in HSCs and/or their microenvironment as key
determinants of relative fitness. More sensitive DNA sequenc-
ing methods may enable detection of very rare cells harbour-
ing known CHIP drivers mutations in similar patient
cohorts, which would lend support to this hypothesis. Stud-
ies of larger numbers of paediatric cancer survivors are
needed to identify rare individuals with CHIP after chemora-
diotherapy, whose particular characteristics may offer insights
into factors facilitating clonal outgrowth of mutated HSCs.
Furthermore, in view of the shifting patterns of mutations
driving CHIP in different adult age groups (McKerrell et al,
2015), selective pressures particular to a less mature bone
marrow environment may confer clonal advantage on a dis-
tinct spectrum of somatic variants in the very young.
Although a much broader screening approach is required to
identify such mutations, the potential role for CHIP as a bio-
marker for patient risk-stratification (Gibson et al, 2017)
may render this a worthwhile endeavour.
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